Schistosoma vaccine
US9283264B2 · kind B2 · utility
0Cited by
0References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 5, 2008 |
| Grant date | Mar 15, 2016 |
| Priority date | — |
| Expiry date | Jun 8, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55566
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The method for large scale production of a full length Schistosomal paramyosin coiled coil dimer composition is carried out by providing a composition comprising recombinant paramyosin, contacting the composition with a strand separation agent to remove paramyosin fragments and other contaminants. The purified paramyosin is used in vaccines for humans and bovine animals to induce immunity against schistosomal infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.